Crenolanib

DB11832InvestigationalSmall molecule

Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3
Curator reviewed
Formula / weight: C₂₆H₂₉N₅O₂ · 443.551 g/mol (avg)
Code names: ARO-002 · CP-868,596

Resolves to

Compound

Structure

InChIKeyDYNHJHQFHQTFTP-UHFFFAOYSA-NSMILESCC1(COC2=CC=C3N(C=NC3=C2)C2=CC=C3C=CC=C(N4CCC(N)CC4)C3=N2)COC1

Targets

What you can answer from here — as of September 05, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

66Drug interactionsStructured to mechanism, not free text

19Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Crenolanib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.